Home > > Global Long-Acting Contraception Market Report
The Long-Acting Contraception market was valued at $1,305.9 Million in 2022, and is projected to reach $2,384.7 Million by 2032 growing at a CAGR of 6.26% from 2023 to 2032.Long-acting contraceptives, also known as long-acting reversible contraceptives (LARCs), are methods of birth control that provide effective pregnancy prevention for an extended period of time without the need for daily, weekly, or monthly maintenance. Examples of LARCs include intrauterine devices (IUDs) and implants. There are several factors that are driving the market for LARCs: Increasing awareness about the effectiveness and convenience of LARCs: As more people become aware of the effectiveness and convenience of LARCs, the demand for these products is likely to increase. Rising prevalence of unintended pregnancies: The high incidence of unintended pregnancies is a major driver of the LARC market. According to the World Health Organization (WHO), approximately 40% of all pregnancies worldwide are unintended, and LARCs can help to reduce this number. Government initiatives and funding: Many governments around the world are promoting the use of LARCs as a means of reducing unintended pregnancies and improving maternal health. This includes providing funding for LARC programs and promoting their use through education and awareness campaigns. Technological advancements: The development of new and improved LARC products is another factor driving the market. For example, the recent introduction of new IUDs with longer-lasting effects and improved safety profiles is likely to increase their adoption. Some of the top companies operating in the LARC market include: Bayer AG: Bayer is a German pharmaceutical and life sciences company that offers a range of LARC products, including the Mirena IUD and the Jaydess IUD. Merck & Co., Inc.: Merck is a global healthcare company that offers the Skyla and Kyleena IUDs, as well as the Implanon implant. Pfizer Inc.: Pfizer is a pharmaceutical company that offers the Depo-Provera injectable contraceptive. Teva Pharmaceutical Industries Ltd.: Teva is an Israeli pharmaceutical company that offers the Paragard IUD. These companies are actively involved in the development of new and improved LARC products, as well as in the promotion of their use through education and awareness campaigns.